(1E,4Z,6E)-5-Hydroxy-1,7-bis-(3-hydroxy-phenyl)-hepta-1,4,6-trien-3-one | 98886-07-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: (1E,4Z,6E)-5-Hydroxy-1,7-bis-(3-hydroxy-phenyl)-hepta-1,4,6-trien-3-one
• 英文别名: (1E,4Z,6E)-5-hydroxy-1,7-bis(3-hydroxyphenyl)hepta-1,4,6-trien-3-one
• CAS: 98886-07-8
• 化学式: C₁₉H₁₆O₄
• 分子量: 308.334
• InChiKey: RDWBDIAZKGAOAH-CTQUXGOISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1E,4Z,6E)-5-Hydroxy-1,7-bis-(3-hydroxy-phenyl)-hepta-1,4,6-trien-3-one 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 2.0h， 以65%的产率得到1,7-bis(3-hydroxyphenyl)heptane-3,5-dione
  参考文献：
  名称：

  A comparative study on the antioxidant properties of tetrahydrocurcuminoids and curcuminoids

  摘要：

  Several curcuminoids and tetrahydrocurcuminoids (THCs), bearing various hydroxyl and/or methoxy groups on their benzene rings, have been synthesized to study their antioxidant and hydrogen donating capacities using the DPPH method at 25 degrees C in methanol. The results show that the tetrahydrocurcuminoids are in general much more efficient than their curcuminoid analogs if they include a phenol group in meta- or para-position of the linking chain and a neighboring phenol or methoxy group. This efficiency gain of THCs by comparison to curcuminoids was attributed to the presence of benzylic hydrogens involved in the oxidation process of these compounds and not to the beta-diketone moiety in the chain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.06.085
• 作为产物：
  描述：

  以 水 为溶剂， 反应 12.0h， 以86%的产率得到(1E,4Z,6E)-5-Hydroxy-1,7-bis-(3-hydroxy-phenyl)-hepta-1,4,6-trien-3-one
  参考文献：
  名称：

  一种人工合成姜黄素及其衍生物的方法

  摘要：

  本发明公开一种人工合成姜黄素及其衍生物的方法。该方法以乙酰丙酮钙为乙酰丙酮供源，经与相应的苯甲醛衍生物进行克莱森‑施密特酯缩合反应并在脱水剂硼酸三正丁酯催化下脱水后得到产物中间体(Ⅰ)姜黄素钙盐；然后中间体(Ⅰ)经一锅法水解得粗品，粗品提纯后得到最终产物姜黄素及其衍生物。与乙酰丙酮硼酸络合物法相比，本发明使用乙酰丙酮钙可以使得反应过程中乙酰丙酮基活性位点更为精确、活化，从而减少副产物的生成，提高姜黄素及其衍生物的产率。

  公开号：

  CN106748705B

文献信息

• COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR
  申请人：HUMAN BIOMOLECULAR RESEARCH INSTITUTE

  公开号：US20160038641A1

  公开（公告）日：2016-02-11

  Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

  描述了由小分子、基质和孤立细胞组成的组合物，包括制备方法，以及动物细胞分化、转分化和增殖成骨母细胞谱系的方法。给细胞施加的或与细胞共培养的成骨材料的示例由独立或首选与基质组合的Formula II、IV和VI化合物代表。受小分子刺激的细胞还与基质结合，与细胞粘合剂或材料载体一起植入到动物体内的部位进行骨修复。预先用Formula II、IV和VI化合物处理的基质也被用于导致细胞迁移到用于治疗目的的基质上。
• Diagnostic Methods and Genetic Markers for Alzheimer Disease
  申请人：Cashman John R.

  公开号：US20090263492A1

  公开（公告）日：2009-10-22

  Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases.

  本发明涉及一种识别患有中枢神经系统疾病（包括阿尔茨海默病、行为障碍等）的个体，以及可用于治疗这些疾病的中枢神经系统药物，其具有更高的治疗效果和更低的副作用的方法和化合物。本发明还涉及一种预测用于治疗中枢神经系统疾病的药物候选品的疗效的方法。该技术还适用于用于神经退行性疾病动物模型的药物发现。
• SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE
  申请人：Cashman John R.

  公开号：US20120040976A1

  公开（公告）日：2012-02-16

  Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for evaluation in animal models of neurodegenerative diseases.

  本发明涉及识别患有中枢神经系统疾病（包括阿尔茨海默病、肌萎缩性侧索硬化症、行为障碍等）的个体，这些个体可以通过使用中枢神经系统药物进行治疗，其治疗效果更好，副作用更小，以及用于此类治疗的化合物。本发明还涉及预测治疗中枢神经系统疾病的候选药物的疗效的方法。该技术还适用于药物发现，以在神经退行性疾病动物模型中进行评估。
• Compounds and matrices for use in bone growth and repair
  申请人：HUMAN BIOMOLECULAR RESEARCH INSTITUTE

  公开号：US10874766B2

  公开（公告）日：2020-12-29

  Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

  描述了小分子、基质和分离细胞的组合物，包括制备方法，以及将动物细胞分化、转分化和增殖为成骨细胞的方法。向细胞施用或与细胞共培养的成骨材料的例子以式 II、IV 和 VI 的化合物为代表，这些化合物可独立使用，或最好与基质结合使用，以产生骨细胞。小分子刺激的细胞也与基质结合，与细胞粘合剂或材料载体一起放置，并植入动物的骨修复部位。用式 II、IV 和 VI 的化合物预处理的基质也用于使细胞迁移到用于治疗目的的基质上。
• Pedersen, Uffe; Rasmussen, Preben B.; Lawesson, Sven-Olov, Liebigs Annalen der Chemie, 1985, # 8, p. 1557 - 1569
  作者：Pedersen, Uffe、Rasmussen, Preben B.、Lawesson, Sven-Olov

  DOI：——

  日期：——